Healx, a Cambridge, UK, technology company developing treatments for rare diseases, today announces the appointment of Dr Neil Thompson, PhD, as Chief Scientific Officer (CSO).
French biotech Osivax has raised €8m to fast-track development of its lead flu vaccine candidate – and branch out to Belgium.
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Harpreet Singh has been appointed the Companys Chief Executive Officer (CEO).
It is one of the largest single private funding rounds a biotech company in Europe has ever pulled off. German biotech BioNTech managed to raise US$325m (€290m) in an upsized Series B round to boost its immuno-oncology pipeline.
Biophytis has priced its IPO on Nasdaq Paris. The company aims to raise up to €10.8m to advance its lead drug candidate under development for the treatment of neuromuscular diseases.
German biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses.
A new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel antibiotics class.
Zelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, announced the appointment of Jens-Peter Marschner as chief medical officer (CMO) at the end of June.
Outgoing EU Commissioner for Agriculture Paul Hogan said in April, that the European Commission will exclude member states from the future Common Agricultural Policy (CAP) that do not include the promotion of the bioeconomy in agriculture.
German researchers have found a way to curb the activity of CAR T cells, even while keeping their cancer-fighting properties intact.